804 related articles for article (PubMed ID: 19559428)
41. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?
Konda VJ; Ross AS; Ferguson MK; Hart JA; Lin S; Naylor K; Noffsinger A; Posner MC; Dye C; Cislo B; Stearns L; Waxman I
Clin Gastroenterol Hepatol; 2008 Feb; 6(2):159-64. PubMed ID: 18096439
[TBL] [Abstract][Full Text] [Related]
42. Outcomes and health-related quality of life after esophagectomy for high-grade dysplasia and intramucosal cancer.
Moraca RJ; Low DE
Arch Surg; 2006 Jun; 141(6):545-9; discussion 549-51. PubMed ID: 16785354
[TBL] [Abstract][Full Text] [Related]
43. Surgical management of high-grade dysplasia in Barrett's esophagus.
Rice TW; Falk GW; Achkar E; Petras RE
Am J Gastroenterol; 1993 Nov; 88(11):1832-6. PubMed ID: 8237928
[TBL] [Abstract][Full Text] [Related]
44. Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Yachimski P; Puricelli WP; Nishioka NS
Gastrointest Endosc; 2009 Feb; 69(2):205-12. PubMed ID: 18950764
[TBL] [Abstract][Full Text] [Related]
45. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in barrett esophagus after endoscopic resection.
Peters F; Kara M; Rosmolen W; Aalders M; Ten Kate F; Krishnadath K; van Lanschot J; Fockens P; Bergman J
Endoscopy; 2005 May; 37(5):418-24. PubMed ID: 15844019
[TBL] [Abstract][Full Text] [Related]
46. Stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia: report on a Brussels' cohort.
Pouw RE; Peters FP; Sempoux C; Piessevaux H; Deprez PH
Endoscopy; 2008 Nov; 40(11):892-8. PubMed ID: 19009481
[TBL] [Abstract][Full Text] [Related]
47. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
48. Surgical treatment of esophageal high-grade dysplasia.
Reed MF; Tolis G; Edil BH; Allan JS; Donahue DM; Gaissert HA; Moncure AC; Wain JC; Wright CD; Mathisen DJ
Ann Thorac Surg; 2005 Apr; 79(4):1110-5; discussion 1110-5. PubMed ID: 15797034
[TBL] [Abstract][Full Text] [Related]
49. [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer].
Etienne J; Dorme N; Bourg-Heckly G; Raimbert P; Fékété F
Bull Acad Natl Med; 2000; 184(8):1731-44; discussion 1744-7. PubMed ID: 11471391
[TBL] [Abstract][Full Text] [Related]
50. Curative treatment for high-grade intraepithelial neoplasia in Barrett's esophagus.
Behrens A; May A; Gossner L; Günter E; Pech O; Vieth M; Stolte M; Seitz G; Ell C
Endoscopy; 2005 Oct; 37(10):999-1005. PubMed ID: 16189774
[TBL] [Abstract][Full Text] [Related]
51. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
52. Salvage cryotherapy after failed radiofrequency ablation for Barrett's esophagus-related dysplasia is safe and effective.
Sengupta N; Ketwaroo GA; Bak DM; Kedar V; Chuttani R; Berzin TM; Sawhney MS; Pleskow DK
Gastrointest Endosc; 2015 Sep; 82(3):443-8. PubMed ID: 25887715
[TBL] [Abstract][Full Text] [Related]
53. Location, location, location: does early cancer in Barrett's esophagus have a preference?
Enestvedt BK; Lugo R; Guarner-Argente C; Shah P; Falk GW; Furth E; Ginsberg GG
Gastrointest Endosc; 2013 Sep; 78(3):462-7. PubMed ID: 23622975
[TBL] [Abstract][Full Text] [Related]
54. Outcomes after liquid nitrogen spray cryotherapy in Barrett's esophagus-associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up.
Ramay FH; Cui Q; Greenwald BD
Gastrointest Endosc; 2017 Oct; 86(4):626-632. PubMed ID: 28235596
[TBL] [Abstract][Full Text] [Related]
55. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
56. Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus.
Small AJ; Sutherland SE; Hightower JS; Guarner-Argente C; Furth EE; Kochman ML; Forde KA; Bewtra M; Falk GW; Ginsberg GG
Gastrointest Endosc; 2015 May; 81(5):1158-66.e1-4. PubMed ID: 25650071
[TBL] [Abstract][Full Text] [Related]
57. Predictors of recurrent specialized intestinal metaplasia after complete laser ablation.
Fisher RS; Bromer MQ; Thomas RM; Cohen S; Krevsky B; Horwitz B; Glazier KD; Das K; Das KM
Am J Gastroenterol; 2003 Sep; 98(9):1945-51. PubMed ID: 14499770
[TBL] [Abstract][Full Text] [Related]
58. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
59. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
60. Barrett's esophagus: management of high-grade dysplasia and cancer.
Ruol A; Zaninotto G; Costantini M; Battaglia G; Cagol M; Alfieri R; Epifani M; Ancona E
J Surg Res; 2004 Mar; 117(1):44-51. PubMed ID: 15013713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
